Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

BioNexus Gene Lab (BGLC) Operating Expenses (2018 - 2025)

BioNexus Gene Lab's Operating Expenses history spans 8 years, with the latest figure at $3.3 million for Q3 2025.

  • For Q3 2025, Operating Expenses rose 54.7% year-over-year to $3.3 million; the TTM value through Sep 2025 reached -$3.7 million, down 117.59%, while the annual FY2024 figure was -$4.9 million, 11.94% down from the prior year.
  • Operating Expenses for Q3 2025 was $3.3 million at BioNexus Gene Lab, up from $1.2 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $6.2 million in Q3 2023 and bottomed at -$7.2 million in Q4 2024.
  • The 5-year median for Operating Expenses is $837648.0 (2022), against an average of $493348.1.
  • The largest annual shift saw Operating Expenses skyrocketed 740.59% in 2021 before it plummeted 506.52% in 2023.
  • A 5-year view of Operating Expenses shows it stood at $647292.0 in 2021, then surged by 50.74% to $975716.0 in 2022, then tumbled by 506.52% to -$4.0 million in 2023, then plummeted by 81.0% to -$7.2 million in 2024, then skyrocketed by 145.89% to $3.3 million in 2025.
  • Per Business Quant, the three most recent readings for BGLC's Operating Expenses are $3.3 million (Q3 2025), $1.2 million (Q2 2025), and -$1.1 million (Q1 2025).